Dose response and safety of telmisartan in patients with mild to moderate hypertension

Journal of Clinical Pharmacology

Volumn 40, Issue 12 I, 2000, Pages 1380-1390

  Smith, David H G ^a   Matzek, Kandace M ^b   Kempthorne Rawson, Joan ^b  

^a Integrated Research   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; PLACEBO; TELMISARTAN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0033751014     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127000004001210     Document Type: Article

References (25)

1. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease
2. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart
3. The myocardial renin-angiotensin system: Existence, importance, and clinical implications
4. Multiple pathways of angiotensin production in the blood vessel walls: Evidence, possibilities, and hypotheses
5. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin
6. The positive association of cough with angiotensin-converting enzyme inhibitors: A therapeutic review
7. Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril: A controlled retrospective cohort study
8. Cough and inhibition of the renin-angiotensin system
9. Angiotensin-II-receptors: New targets for antihypertensive therapy
10. Pharmacological characterisation of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
11. Telmisartan
12. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients
13. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension
14. Once-daily telmisartan compared with enalapril in the treatment of hypertension
15. 1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension
16. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension
17. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine
18. The efficacy and safety of telmisartan compared to atenolol and placebo in patients with hypertension
19. The long-term safety and efficacy of telmisartan compared to atenolol in the treatment of hypertension
20. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild to moderate hypertension
21. The incidence of cough: A comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist
22. 14C]telmisartan in healthy volunteers
23. Blood pressure variability: Clinical implications and effects of antihypertensive treatment
24. Role of trough to peak efficacy in the evaluation of antihypertensive therapy
25. The inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge